User profiles for R. La Joie
Renaud La JoieMemory and Aging Center; Department of Neurology; University of California, San Francisco Verified email at ucsf.edu Cited by 13315 |
[HTML][HTML] Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
Recent developments of PET amyloid ligands have made it possible to visualize the
presence of Aβ deposition in the brain of living participants and to assess the consequences …
presence of Aβ deposition in the brain of living participants and to assess the consequences …
Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease
Hippocampal atrophy, as evidenced using magnetic resonance imaging (MRI), is one of the
most validated, easily accessible and widely used biomarkers of Alzheimer’s disease (AD). …
most validated, easily accessible and widely used biomarkers of Alzheimer’s disease (AD). …
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …
The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features
A ‘frontal variant of Alzheimer’s disease’ has been described in patients with predominant
behavioural or dysexecutive deficits caused by Alzheimer’s disease pathology. The …
behavioural or dysexecutive deficits caused by Alzheimer’s disease pathology. The …
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic …
… (r) and Spearman's (r s ) coefficients. Correlations between biomarkers and cognitive tests,
which were not normally distributed, were calculated using Spearman rank tests (r s ). The …
which were not normally distributed, were calculated using Spearman rank tests (r s ). The …
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid …
… and amyloid PET across all participants (R 2 , 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid
PET];P< .001, bootstrapped for difference) in the Aβ-positive MCI group (R 2 , 0.25 [tau PET] …
PET];P< .001, bootstrapped for difference) in the Aβ-positive MCI group (R 2 , 0.25 [tau PET] …
Four distinct trajectories of tau deposition identified in Alzheimer's disease
… Model accuracy was represented as the r 2 between the mean observed ROI-level tau PET
… For each subtype, we compared the r 2 of the model using the best-fitting epicenter to the r 2 …
… For each subtype, we compared the r 2 of the model using the best-fitting epicenter to the r 2 …
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease
Neuropathological and in vivo studies have revealed a tight relationship between tau
pathology and cognitive impairment across the Alzheimer’s disease spectrum. However, tau …
pathology and cognitive impairment across the Alzheimer’s disease spectrum. However, tau …
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies,
simple, widely available screening tests are needed to identify which individuals, who are …
simple, widely available screening tests are needed to identify which individuals, who are …
Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET
… In addition, this full model roughly explained the same amount of variance (marginal R 2
= 0.426, conditional R 2 = 0.800) as the model including baseline FTP PVC only and had a …
= 0.426, conditional R 2 = 0.800) as the model including baseline FTP PVC only and had a …